Get the Daily Brief
Latest Biotech News
Regulatory approvals and label expansions
Celcuity’s Revtorpyk (gedatolisib) cleared an FDA approval step for previously treated HR+/HER2−, PIK3CA-wildtype hormone receptor-positive, HER2-negative breast cancer, establishing a new...
Phase 3 oncology efficacy readouts and competitive standard-of-care shifts
Merck’s targeted chemotherapy sac-TMT posted additional phase 3 momentum from China, with sac-TMT plus Keytruda delaying tumor progression versus chemotherapy plus Keytruda in first-line...
Tau therapeutics and Alzheimer’s late-stage positioning
Biogen’s diranersen (BIIB-080) generated a renewed case for phase 3 escalation after phase 2 Celia data presented at AAIC showed cognitive slowdown roughly on par with approved anti-amyloid...
Big Pharma licensing and rights deals for oncology platforms
AstraZeneca signed a licensing agreement for Dizal Pharmaceutical’s EGFR exon 20 insertion drug Zegfrovy (sunvozertinib), paying $600 million upfront and making the deal worth up to $1.5 billion...
Oncology manufacturing science: ADC potency and analytic/manufacturing implications
A new design method reported in the ADC space claims to increase potency against heterogeneous tumors by improving how antibody-drug conjugates engage multi-receptor biology. The approach targets...
Funding and public-market pipeline for biotech IPOs and new listings
Attovia filed for an initial public offering, positioning the company for public-market funding behind IL-31-targeting immunology assets aimed at severe itching conditions. The listing ambition...
Radiopharmaceutical financing to scale next-gen prostate cancer agents
AdvanCell raised a $315 million Series D to advance its lead-based prostate cancer radiopharmaceutical program and to shore up U.S. manufacturing capacity for its radioactive therapy pipeline. The...
Cell and gene therapy manufacturing: modular models, AI control, and automation
Researchers outlined modular mechanistic modeling strategies aimed at improving mRNA manufacturing efficiency and robustness by decomposing in vitro transcription into reusable mechanistic...
FDA policy and regulatory frameworks affecting drug development and manufacturing
The FDA proposed changes to simplify registration for advanced distributed manufacturing establishments using a hub-and-spoke model, aiming to reduce administrative burden when multiple...
Clinical development setbacks and pipeline pruning at Big Pharma
Johnson & Johnson discontinued development of its geographic atrophy eye disease gene therapy JNJ-1887 after reviewing top-line phase 2b Parasol trial data. The company confirmed the geographic...
FDA approval in breast cancer (PI3K pathway inhibition)
Celcuity won FDA approval for gedatolisib (Revtorpyk), a small-molecule PI3K inhibitor, for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who have no...
AstraZeneca licensing expansion for EGFR exon 20 NSCLC
AstraZeneca agreed to license exclusive global rights to Dizal Pharmaceutical’s oral EGFR inhibitor Zegfrovy (sunvozertinib), a deal potentially worth up to $1.5 billion. The transaction follows...
Biogen’s tau antisense progress heads to Phase 3
Biogen’s diranersen (BIIB-080) delivered clinical and biomarker signals in the Phase II Celia trial that Biogen is using to support a Phase III push, despite missing the trial’s primary...
Biotech manufacturing innovation: FDA moves to streamline distributed manufacturing registrations
The FDA proposed a rule to streamline establishment registration for distributed manufacturing using a hub-and-spoke model, allowing the network to register as a single establishment rather than...
New FDA-enabled cell therapy modality: allogeneic Treg treatment enters approvals
FDA’s June approvals included Tregzi (Orca-T), described as the first approved allogeneic regulatory T cell-based therapy for hematological malignancies in matched-donor hematopoietic stem cell...
Funding: Nava Therapeutics raises for bone-marrow, immune, and kidney-targeted lipid nanoparticles
Nava Therapeutics raised $89 million to advance a new class of lipid nanoparticles aimed at targeting bone marrow, immune cells, and the kidney. The startup, described as secretive, intends to use...
Startup launch and AI manufacturing: Insilico and Bora Pharma create an AI-driven biologics CDMO entity
Insilico Medicine and Taiwan-based Bora Pharmaceuticals announced plans to launch a new AI-driven manufacturing company for biologics. The initiative is designed to compete with service providers...
Clinical development funding: Draig secures Series B to advance an AMPA receptor potentiator
Draig Therapeutics raised $65 million in an oversubscribed Series B to move DT-101, its AMPA receptor potentiator, through Phase III programs in major depressive disorder. The Cardiff University...
IPO pipeline: Attovia files for IPO to fund clinical development
Attovia Therapeutics filed for an initial public offering as biotech listings continue to build momentum. The filing supports the company’s plan to fund pipeline advancement and commercialization...
Biomanufacturing innovation: Cellares and Sonoma automate engineered Treg cell therapy production
Cellares and Sonoma Biotherapeutics agreed to automate manufacturing for SBT-77-7101, an engineered regulatory T cell therapy in Phase I development for poly-refractory rheumatoid arthritis....